BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “The FLRT3-UNC5B Checkpoint Pathway Inhibits T Cell-Based Cancer Immunotherapies” in the… Read More..

PITTSBURGH, March 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for clinical testing… Read More..

SANTA BARBARA, CA / ACCESSWIRE / March 5, 2024 / DRYWORLD Brands Inc. (OTC PINK:IBGR), a premium performance sports brand, today shared a corporate update highlighting its growth in 2023 and the company's outlook for 2024. Notably, the company notched 1,700% growth in Q1 2024 sales as compared to the… Read More..